DCPIB
Based on 11 publication(s) in Google Scholar
DCPIB is a selective, reversible and potent inhibitor of volume-regulated anion channels (VRAC). DCPIB voltage-dependently activates potassium channels TREK1 and TRAAK, and inhibits TRESK, TASK1 and TASK3 (IC50s: 0.14, 0.95, 50.72 μM, respectively). DCPIB is also a selective blocker of swelling-induced chloride current (ICl,swell), with an IC50 of 4.1 μM. DCPIB is a useful tool for investigating structure-function studies of K2P channels.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.89%
- CAS No.: 82749-70-0
- Formule: C22H28Cl2O4
- Masse moléculaire:427.36
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
Mechanoreceptors Compound Library
HY-L095
-
Targeted Diversity Library
HY-L099
-
Potassium Channel Compound Library
HY-L119
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Inhibitors Library
HY-L158
-
Ion Channel Compound Library
HY-L166
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) DCPIB
More- Signal Transduct Target Ther. 2024 Dec 30;9(1):367. [Abstract]
- J Transl Med. 2024 Aug 22;22(1):785. [Abstract]
- Sci China Life Sci. 2025 Feb 20. [Abstract]
- Cell Chem Biol. 2025 Jun 19;32(6):885-898.e11. [Abstract]
- Biochem Pharmacol. 2026 Mar:245:117688. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2024 Feb 11;1870(4):167066. [Abstract]
- Cell Calcium. 2023 May:111:102715. [Abstract]
- Oncol Rep. 2023 Jun;49(6):115. [Abstract]
- Biochem J. 2023 May 17;480(9):701-713. [Abstract]
- Mol Pain. 2025 Jan-Dec:21:17448069251324645. [Abstract]
- bioRxiv. 2024 Apr 18:2023.08.31.555808. [Abstract]
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
WB
Activité biologique
IC50：0.14 μM (TRESK), 0.95 μM (TASK1), 50.72 μM (TASK3)[1], 4.1 μM (ICl,swell, CPAE cells)[2]
DCPIB (10 μM) activates TREK1 and enhances TRAAK currents in COS-7 cells[1].
DCPIB (10 μM) prominently and reversibly suppresses TRESK currents in COS-7 cells, with an IC50 of 0.14 μM[1].
DCPIB (10 μM) displays selectivity for ICl,swell and has no significant inhibitory effects on ICl,Ca in CPAE cells[2].
DCPIB (10 μM, 5 min) has no effect on attenuate subsequent swelling in cardiomyocytes[2].
DCPIB (10 μM, 3 h) inhibits LPS-induced MAPK activation in BV2 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:BV2 cells
-
Concentration:10 μM
-
Incubation Time:3 h
-
Result:Significantly decreased Ki67 positive staining microglia and pro-inflammatory cytokine (TNF-α, IL-1β) secretion.
-
Cell Line:BV2 cells
-
Concentration:10 μM
-
Incubation Time:3 h
-
Result:Inhibited migratory potential of transient OGD (Oxygen-glucose deprivation) exposed BV2 cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Reversible middle cerebral artery occlusion (rMCAO) model[3]
-
Dosage:1 mM, 10 μL
-
Administration:Administered manually for 20s by intracerebroventricular infusion
-
Result:Diminished Pyramidal neurons injury induced by rMCAO in the CA1 region.
Chemical Information
-
CAS No. 82749-70-0
-
Appearance Solid
-
Masse moléculaire 427.36
-
Formule C22H28Cl2O4
-
Color White to off-white
-
SMILES
O=C(O)CCCOC1=CC2=C(C(C(C3CCCC3)(CCCC)C2)=O)C(Cl)=C1Cl
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
2024 Dec 30;9(1):367. PMID: 39737965
DCPIB purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2024 Dec 30;9(1):367. [Abstract]
IRF2BP2 protein abundance was visualized by immunoblotting in BMDMs isolated from Hspa5f/f or Hspa5f/f; Lyz2-Cre mice. These CHX-treated BMDMs were treated with/without ArA or DCPIB (DB) (100 μM; 9 h). The results showed that DB protected IRF2BP2 from degradation in a BiP-dependent manner.
-
J Transl Med
ML335 inhibits TWIK2 channel-mediated potassium efflux and attenuates mitochondrial damage in MSU crystal-induced inflammation. [Abstract]2024 Aug 22;22(1):785. PMID: 39175013 -
Sci China Life Sci
2025 Feb 20. PMID: 39985646
DCPIB purchased from MedChemExpress. Usage Cited in: Sci China Life Sci. 2025 Feb 20. [Abstract]
DCPIB (20 μM) blocked SWELL1 activity and decreased the proportion of high-response cells to 65.9%.
-
Cell Chem Biol
Electrochemical sensor toolkit for simultaneous glutamate detection at edge of cleft and peri-soma. [Abstract]2025 Jun 19;32(6):885-898.e11. PMID: 40466640 -
Biochem Pharmacol
2026 Mar:245:117688. PMID: 41506545 -
Biochim Biophys Acta Mol Basis Dis
LRRC8A as a central mediator promotes colon cancer metastasis by regulating PIP5K1B/PIP2 pathway. [Abstract]2024 Feb 11;1870(4):167066. PMID: 38350542 -
Cell Calcium
The Ca2+ channel TRPV4 is dispensable for Ca2+ influx and cell volume regulation during hypotonic stress response in human keratinocyte cell lines. [Abstract]2023 May:111:102715. PMID: 36933289 -
Oncol Rep
Paclitaxel induces pyroptosis by inhibiting the volume‑sensitive chloride channel leucine‑rich repeat‑containing 8a in ovarian cancer cells. [Abstract]2023 Jun;49(6):115. PMID: 37083067 -
Biochem J
LRRC8A is responsible for exosome biogenesis and volume regulation in colon cancer cells. [Abstract]2023 May 17;480(9):701-713. PMID: 37129855 -
Mol Pain
Upregulation of LRRC8A in the anterior cingulate cortex mediates chronic visceral pain in adult male mice with neonatal maternal deprivation. [Abstract]2025 Jan-Dec:21:17448069251324645. PMID: 39962353 -
bioRxiv
Cytoskeletal activation of NHE1 regulates mechanosensitive cell volume adaptation and proliferation. [Abstract]2024 Apr 18:2023.08.31.555808. PMID: 37693593
Solvant et solubilité
DMSO : 100 mg/mL (233.99 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.87 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (4.87 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.08 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (278 KB)
-
SDS (641 KB)
- English - EN (641 KB)
- Français - FR (641 KB)
- Deutsch - DE (641 KB)
- Norwegian - NO (641 KB)
- Español - ES (641 KB)
- Swedish - SV (641 KB)
- Italian - IT (641 KB)
- Korean - KR (641 KB)
- Portuguese - PT (641 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Lv J, et al. DCPIB, an Inhibitor of Volume-Regulated Anion Channels, Distinctly Modulates K2P Channels. ACS Chem Neurosci. 2019 Apr 17. [Content Brief]
[2]. Decher N, et al. DCPIB is a novel selective blocker of I(Cl,swell) and prevents swelling-induced shortening of guinea-pig atrial action potential duration. Br J Pharmacol. 2001 Dec;134(7):1467-79. [Content Brief]
[3]. Qingdong Han, et al. DCPIB, a potent volume-regulated anion channel antagonist, attenuates microglia-mediated inflammatory response and neuronal injury following focal cerebral ischemia. Brain Res. 2014 Jan 13;1542:176-85. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3399 mL | 11.6997 mL | 23.3995 mL | 58.4987 mL |
| 5 mM | 0.4680 mL | 2.3399 mL | 4.6799 mL | 11.6997 mL | |
| 10 mM | 0.2340 mL | 1.1700 mL | 2.3399 mL | 5.8499 mL | |
| 15 mM | 0.1560 mL | 0.7800 mL | 1.5600 mL | 3.8999 mL | |
| 20 mM | 0.1170 mL | 0.5850 mL | 1.1700 mL | 2.9249 mL | |
| 25 mM | 0.0936 mL | 0.4680 mL | 0.9360 mL | 2.3399 mL | |
| 30 mM | 0.0780 mL | 0.3900 mL | 0.7800 mL | 1.9500 mL | |
| 40 mM | 0.0585 mL | 0.2925 mL | 0.5850 mL | 1.4625 mL | |
| 50 mM | 0.0468 mL | 0.2340 mL | 0.4680 mL | 1.1700 mL | |
| 60 mM | 0.0390 mL | 0.1950 mL | 0.3900 mL | 0.9750 mL | |
| 80 mM | 0.0292 mL | 0.1462 mL | 0.2925 mL | 0.7312 mL | |
| 100 mM | 0.0234 mL | 0.1170 mL | 0.2340 mL | 0.5850 mL |
DCPIB Related Classifications
HY-103371 Related Classifications
Powered by Bioz